Academic Bibliography

Show Sort by

Your filters: cql: parent exact "Blood"

Mark
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

Sara El Ashkar, Juerg Schwaller, Tim Pieters (UGent) , Steven Goossens (UGent) , Jonas Demeulemeester, Frauke Christ, Siska Van Belle, Sabine Juge, Nancy Boeckx, Alan Engelman, et al.

(2018) BLOOD. 131(1). p.95-107
Mark
Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia

Steven Goossens (UGent) , Sofie Peirs (UGent) , Wouter Van Loocke (UGent) , Jueqiong Wang, Mina Takawy, Filip Matthijssens (UGent) , Stefan E Sonderegger, Katharina Haigh, Thao Nguyen, Niels Vandamme (UGent) , et al.

(2017) BLOOD. 129(8). p.981-990
Mark
The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling

Jin Li, Tamara Riedt, Steven Goossens (UGent) , Carmen Carrillo Garcia, Sabrina Szczepanski, Maria Brandes, Tim Pieters (UGent) , Linne Dobrosch, Ines Guetgemann, Natalie Farla (UGent) , et al.

(2017) BLOOD. 129(4). p.460-472
Mark
- conference
- C3
Highly variable frequencies of donor antigen-specific naive cells may dictate the immunogenicity of minor histocompatibility antigens after hematopoietic stem cell transplantation

Anna Kuchmiy (UGent) , Savely Sheetikov, Dmitrii Romaniuk, Anna Postovskaya, Sergey Filkin, Nadia Bykova, Grigory Efimov and Valeriy G. Savchenko

(2017) BLOOD. 130(suppl. 1).
Mark
- misc
Novel oncogenic noncoding mutations in T-ALL

Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)

(2017) BLOOD. 129(24). p.3140-3142
Mark
- conference
- C3
IFM2012-03

Xavier Leleu, Guillemette Fouquet, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Jv Malfuson, Pascal Bourquard, Pascal Lenain, et al.

(2016) BLOOD. 128(22).
Mark
Genomic landscape of pediatric mixed phenotype acute leukemia

Thomas B Alexander, Zhaohui Gu, John K Choi, Mignon Loh, John Horan, Barbara Buldini, Giuseppe Basso, Sarah Elitzur, Valerie de Haas, C Michel Zwaan, et al.

(2016) BLOOD. 128(22).
Mark
Prognostic discrimination of children and adolescents with chronic myeloid leukemia based on the EUTOS Long Term Survival (ELTS) score

Frédéric Millot, Joelle Guilhot, Meinolf Suttorp, Adalet Meral Günes, Petr Sedlacek, Eveline de Bont, Chi Kong Li, Krzysztof Kalwak, Birgitte Lausen, Srdjana Culic, et al.

(2016) BLOOD. 128(22).
Mark
- conference
- C3
Therapeutic targeting of the histone ubiquitination-methylation axis in T cell leukemia

Panagiotis Ntziachristos, Kelly Arcipowski, Carlos Alberto Martinez, Yixing Zhu, Andrew G Volk, Suresh Kumar, Paul M Thomas, Pieter Van Vlierberghe (UGent) , Nobuko Hijiya, Stacy Marshall, et al.

(2016) BLOOD. 128(22).
Mark
- conference
- C3
Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia

Paul Barr, Tadeusz Robak, Carolyn J Owen, Alessandra Tedeschi, Osnat Bairey, Nancy L Bartlett, Jan Burger, Peter Hillmen, Steven Coutre, Stephen Devereux, et al.

(2016) BLOOD. 128(22).

Academic Bibliography

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia

The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling

Highly variable frequencies of donor antigen-specific naive cells may dictate the immunogenicity of minor histocompatibility antigens after hematopoietic stem cell transplantation

Novel oncogenic noncoding mutations in T-ALL

IFM2012-03

Genomic landscape of pediatric mixed phenotype acute leukemia

Prognostic discrimination of children and adolescents with chronic myeloid leukemia based on the EUTOS Long Term Survival (ELTS) score

Therapeutic targeting of the histone ubiquitination-methylation axis in T cell leukemia

Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia

Contents

Support

Contact